| Nov 17 |
Tivic Health Systems Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)
|
| Nov 15 |
Tivic hits enrolment target for vagus nerve stimulation trial
|
| Nov 15 |
Tivic Health Systems GAAP EPS of -$0.23, revenue of $126K
|
| Nov 15 |
Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 14 |
Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 12 |
Tivic Health Validates European Patents in Great Britain, Germany, and France
|
| Nov 7 |
Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14
|
| Oct 29 |
First Subject Enrolled in Tivic Health’s Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device
|
